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Abstract
Inhibition of the functional activity of Filamenting temperature-sensitive mutant Z (FtsZ) protein, an essential and highly
conserved bacterial cytokinesis protein, is a promising approach for the development of a new class of antibacterial agents.
Berberine, a benzylisoquinoline alkaloid widely used in traditional Chinese and native American medicines for its
antimicrobial properties, has been recently reported to inhibit FtsZ. Using a combination of in silico structure-based design
and in vitro biological assays, 9-phenoxyalkyl berberine derivatives were identified as potent FtsZ inhibitors. Compared to
the parent compound berberine, the derivatives showed a significant enhancement of antibacterial activity against clinically
relevant bacteria, and an improved potency against the GTPase activity and polymerization of FtsZ. The most potent
compound 2 strongly inhibited the proliferation of Gram-positive bacteria, including methicillin-resistant S. aureus and
vancomycin-resistant E. faecium, with MIC values between 2 and 4 mg/mL, and was active against the Gram-negative E. coli
and K. pneumoniae, with MIC values of 32 and 64 mg/mL respectively. The compound perturbed the formation of cytokinetic
Z-ring in E. coli. Also, the compound interfered with in vitro polymerization of S. aureus FtsZ. Taken together, the chemical
modification of berberine with 9-phenoxyalkyl substituent groups greatly improved the antibacterial activity via targeting
FtsZ.
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Introduction
Antibiotic resistance is an alarming health problem worldwide.
Antibiotic misuse creates selective pressure for survival of resistant
bacterial strains and, consequently, many clinically used antibiotics
such as b-lactams, aminoglycosides, tetracyclines and sulfon-
amides, are becoming ineffective against antibiotic-resistant
bacteria [1,2]. Infections associated with methicillin-resistant
Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus
faecium (VREF) have resulted in increasing nosocomial health
concerns for both patients and medical professionals [3,4]. Thus,
there is an urgent need for new antibacterial agents with
innovative mechanisms of action.
Filamenting temperature-sensitive mutant Z (FtsZ), an analogue
of eukaryotic tubulin, is an essential and highly conserved bacterial
cytokinesis protein [5]. During bacterial cell division, FtsZ
monomers self-assemble into a Z-ring, a highly dynamic cytoskel-
eton scaffold generated at the site of septum formation [6,7]. The
mechanism regulating assembly and organization of FtsZ into a
ring-like structure involves GTP binding and hydrolysis, modu-
lated by the interaction of the N-terminal nucleotide binding
domain of one FtsZ monomer with the C-terminal GTPase-
activating domain (T7-loop) on the adjacent FtsZ monomer [8].
Subsequently, FtsZ recruits other proteins to form a cell-division
complex known as the divisome. Once the divisome is fully
assembled, bacterial cell division is achieved by coordinated
constriction and splitting of the daughter cells [9,10].
Recent studies suggest that inhibition of bacterial cell division
proteins with an essential role in bacterial cytokinesis, such as FtsZ,
is a promising approach against antibiotic-resistant bacterial
infections [11–13]. A number of small molecule inhibitors of FtsZ
have already been shown to prevent FtsZ polymerization and
inhibit bacterial cell division [14–20]. The molecules bind to one
of two alternative sites of FtsZ (Figure 1A): at the N-terminal GTP
binding site [21–23], or at the C-terminal interdomain cleft [24].
Compounds targeting the highly conserved GTP binding site
mimic the natural substrate of the enzyme and might have
potential advantages for developing broad-spectrum antibacterial
agents [25]. However, because GTP binding sites are present in a
number of human proteins, GTP-mimetic compounds might have
potential liabilities related to the off-target-associated activity.
Thus, the C-terminal interdomain cleft formed by residues from
the C-terminal b-sheet, T7-loop and H7-helix, offers an alterna-
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tive opportunity for the design of FtsZ inhibitors with therapeutic
potential in antibiotic-resistant bacterial diseases [26].
Berberine (Figure 2) is a plant alkaloid with a long history of
medicinal use in traditional Chinese and native American
medicines [27]. Berberine extracts show significant antimicrobial
activity against bacteria, viruses and fungi. Its potential mecha-
nisms of antimicrobial activity include the suppression of cell
adhesion and migration [28], and inhibition of microbial enzymes
[29]. Moreover, recent literature reports demonstrated that
berberine is active against Gram-positive bacteria with minimum
inhibitory concentration values (MIC) in the range of 100–
400 mg/mL by targeting the cell division protein FtsZ [30,31].
Therefore, berberine is an attractive lead for the development of
potent FtsZ inhibitors. Given the availability of X-ray crystal
structures of FtsZ [7,24,32,33], molecular docking is particularly
appealing for guiding the chemical derivatization of berberine.
Previous studies suggested that berberine binds FtsZ in a
hydrophobic pocket [14]. In this paper we report the design and
biological study of a series of 9-phenoxyalkyl berberine derivatives
with potent inhibition of FtsZ GTPase activity and broad-
spectrum of antibacterial activity.
Materials and Methods
Molecular Docking Simulation of Berberine and its 9-
phenoxyalkyl Derivatives
The ICM molecular modeling package v3.6 was used for all
computational studies. The X-ray crystal structure of the S. aureus
FtsZ with bound GDP and PC190723 (PDB code: 4DXD) [24]
was retrieved from the RCSB Protein Data Bank (http://www.
rcsb.org) and prepared for docking using an automated protein
preparation protocol [34]. The co-crystal ligands PC190723 and
GDP were deleted before docking, as well as the water molecules.
The N-terminal GTP binding site and the C-terminal interdomain
cleft of S. aureus FtsZ were analyzed with the PocketFinder function
in the ICM software [35]. Ligand binding pocket surfaces were
colored according to their binding properties. Berberine was built
using the ICM ligand editor, converted into 3D and minimized.
The compound was docked against the N-terminal GTP binding
site and the C-terminal interdomain cleft of S. aureus FtsZ. The
sites were limited to FtsZ residues with at least one non-hydrogen
atom within a 10 A˚ cutoff radius from the GDP and the PC190723
co-crystals, respectively. The pockets were represented by grid
potential maps accounting for hydrogen bonding, hydrophobic,
van der Waals, and electrostatic interactions. A grid spacing of 0.5
A˚ was used. Berberine was flexibly docked and scored according to
the ICM scoring function. One hundred independent docking
runs were performed at each site and the poses were clustered by
heavy atom root-mean-square deviation (RMSD). The top-scoring
results were selected and visually inspected.
A set of 9-substituted berberine derivatives (1–7) was docked
against the X-ray crystal structure of S. aureus FtsZ using the same
docking protocol.
Materials and Measurement
Berberine chloride was purchased from Sigma-Aldrich. The 9-
phenoxyalkyl substituted berberine derivatives (Figure 2) were
synthesized according to the procedures described by Li et al. [36].
1H NMR spectra were obtained with a Bruker 400 MHz DPX-
Figure 1. Predicted binding modes of berberine and 9-phenoxyalkyl substituted derivatives. (A) S. aureus FtsZ (PDB code: 4DXD) with
PC190723 bound to the C-terminal interdomain cleft, and GDP bound to the N-terminal GTP binding site. (B) Predicted binding mode of berberine
into the C-terminal interdomain cleft. (C) Predicted binding mode of compound 2 into the C-terminal interdomain cleft. The FtsZ pockets are colored
by binding properties (white = neutral surface, green = hydrophobic surface, red = hydrogen bonding acceptor potential, and blue = hydrogen
bond donor potential. Ligand atoms are shown with a ‘ball and sticks’ representation and colored in yellow (carbon), red (oxygen), blue (nitrogen),
orange (phosphorus) and green (chloride). Interacting FtsZ residues are labeled and shown with white carbons.
doi:10.1371/journal.pone.0097514.g001
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400 NMR spectrometer. Mass spectra were recorded with a
Finnigan MAT 95S mass spectrometer. All reactions were
monitored by thin layer chromatography on silica gel. The
synthesis of these derivatives and their 1H NMR and mass spectra
can be referred to Text S1 in the supporting information.
Bacterial Strains and Reagents
The bacterial strains S. aureus ATCC 29213, S. aureus ATCC
29247, S. aureus ATCC BAA-41, E. faecium ATCC 49624, E.
faecium ATCC 700221, E. faecalis ATCC 29212, S. epidermidis
ATCC 12228, E. coli ATCC 25922, and K. pneumoniae ATCC
BAA-1144 used in the antimicrobial susceptibility assays were
purchased from American Type Culture Collection (ATCC,
USA). B. subtilis strain 168 was already available in our in-house
collection. E. coli JM109 WM647 was kindly provided by Dr. W.
Margolin (University of Texas-Houston Medical School). FM 4–
64 was purchased from Invitrogen (Eugene, Oregon). All other
chemicals and reagents were purchased from Sigma-Aldrich.
Stock solutions were prepared in DMSO. The final percentage of
DMSO in the assays was 1% (v/v) for all experiments.
Expression and Purification of S. aureus FtsZ
E. coli BL21(DE3) cells were transformed with the pRSET-A-S
vector carrying S. aureus FtsZ with a 6-histidine tag attached at its
N-terminus under the control of a T7 promoter [37]. The
transformed E. coli strain was streaked on a nutrient agar plate
containing 50 mg/mL ampicillin, and the agar plate was incubated
at 37uC overnight. A single colony was inoculated into 5 mL of
Luria–Bertani (LB) medium in the presence of 50 mg/mL
ampicillin, which was then incubated at 37uC, with shaking at
250 rpm for 16 h. The overnight culture was transferred into a
fresh 26TY medium in a dilution ratio of 1:100 and 50 mg/mL
ampicillin was then added, followed by incubation at 37uC with
shaking at 250 rpm. When the OD600 reached 0.8, protein
expression was induced with 0.4 mM isopropyl-b-D-thiogalacto-
pyranoside (IPTG) for 4 h. Cells were harvested by centrifugation
at 9000 rpm for 20 min at 4uC. The cell pellet was resuspended in
20 mL of solubilization buffer (50 mM Tris-HCl, 150 mM NaCl,
1 mM PMSF and 1 mM EDTA, pH 7.4) and then lysed with
1 mg/mL of lysozyme. The mixture was incubated for 1 h on ice.
The cells were disrupted by sonication and the crude lysate
obtained was centrifuged at 13,000 rpm for 1 h at 4uC. The
supernatant containing 6-histidine tagged S. aureus FtsZ was
collected and loaded onto a nickel charged HiTrap chelating
column pre-equilibrated with starting buffer (20 mM sodium
phosphate buffer, 0.5 M NaCl, pH 7.4). The column was then
washed with 8 column volumes of the starting buffer to remove the
unbound proteins, and the histidine-tagged enzyme was eluted by
a linear gradient of 020.2 M imidazole. Fractions containing S.
aureus FtsZ were pooled, buffer-exchanged with 20 mM
NH4HCO3 (pH 8.0) at 4uC, lyophilized, and stored at 220uC.
A stock solution of S. aureus FtsZ for the subsequent bioassay was
prepared from the lyophilized powder.
Antimicrobial Susceptibility Assays
Antimicrobial susceptibility tests were conducted in 96-well
microplates using the broth microdilution procedure described in
the Clinical and Laboratory Standards Institute (CLSI) guidelines
[38]. Cation-adjusted Mueller Hinton broth for S. aureus strain
ATCC 29213, methicillin-resistant S. aureus strain ATCC BAA-41
and ampicillin-resistant S. aureus strain ATCC 29247, or brain
heart infusion broth for antibiotic-susceptible E. faecium strain
ATCC 49624 and vancomycin-resistant E. faecium strain ATCC
700221, or Mueller Hinton broth for antibiotic-susceptible strains
B. subtilis strain 168, E. faecalis strain ATCC 29212 and E. coli
strain ATCC 25922 were used in the assays. After incubation for
Figure 2. Chemical structures of berberine and its 9-phenoxyalkyl substituted derivatives.
doi:10.1371/journal.pone.0097514.g002
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18 h at 37uC, the absorbance at 600 nm (A600) was recorded using
a microplate reader (Bio-Rad laboratory Ltd., UK) and the
percentage of bacterial cell inhibition with respect to vehicles (1%
DMSO) was calculated. The MIC was defined as the lowest
compound concentration at which the growth of bacteria was
inhibited by$90%. Three independent assays were performed for
each test.
GTPase Activity Assay
The GTPase activity of recombinant S. aureus FtsZ was
measured in 96-well microplates using a CytoPhos phosphate
assay Biochem Kit (Cytoskeleton, USA) according to an optimized
protocol and the manufacturer’s instructions. S. aureus FtsZ
(3.5 mM) was preincubated with vehicle (1% DMSO) or different
concentrations of each test compound in 50 mM 4-morpholine-
propanesulfonic acid buffer (MOPS, pH 6.5) for 10 min at 25uC.
Then 5 mM of MgCl2 and 200 mM of KCl were added.
Reactions were started with the addition of 500 mM GTP and
incubated at 37uC. After 30 min, the reactions were quenched by
adding 100 mL of Cytophos reagent for 10 min. Inorganic
phosphate was quantified by measuring the absorbance at
650 nm with a microplate reader (Bio-Rad laboratory Ltd.,
UK). The relative IC50 values were determined by nonlinear
regression using a sigmoidal concentration-response curve in the
Origin software v6. For the rate of GTPase activity of S. aureus
FtsZ, different concentrations of fresh prepared FtsZ (3, 6, 9, 12,
15 mM) was preincubated with vehicle (1% DMSO) or 25 mM,
50 mM compound 2, following the same condition. The data were
plotted via Origin software v6. Three independent assays were
performed for all the tests.
Light Scattering Assay
The light scattering assay was performed using a protocol
adapted from the literature [39]. The polymerization and
depolymerization of recombinant S. aureus FtsZ was measured
using 90u light scattering in a thermostatically (37uC) controlled
fluorescence spectrometer (Perkin Elmer, USA). Both excitation
and emission wavelengths were set to 600 nm with a slit width of
2.5 nm. S. aureus FtsZ (6 mM) in 50 mM of MOPS buffer (pH 6.5)
was incubated with vehicle (1% DMSO) or different concentra-
tions of the test compound for 10 min at 25uC. 50 mM KCl and
10 mM MgCl2 were then added to establish a baseline. After
8 min, a final concentration of 1 mM GTP was added at the last
fraction and the increase in light scattering was measured for an
additional 2000s. The rate and extent of polymerization were
measured. Appropriate blanks were subtracted from all experi-
mental data. Moreover, in order to rule out unselective inhibition
by formation of aggregates, control experiments with 0.01% (v/v)
Triton X-100 from a freshly prepared 1% (v/v) stock solution were
performed for berberine and compound 2 [40,41]. Reported
results are the average of three independent experiments.
Transmission Electron Microscopy (TEM)
S. aureus FtsZ (12 mM) was incubated in the absence and in the
presence of different concentrations of the test compounds in
50 mM MOPS buffer (pH 6.5) at 25uC. After 10 min, 5 mM
MgCl2, 50 mM KCl, and 1 mM GTP were added to the reaction
mixtures and incubated at 37uC for 15min. Then, 10 mL of the
sample mixtures were placed on a glow-discharged Formvar
carbon-coated copper grid (400 mesh) for 10 min. The grids were
subsequently subjected to negative staining using 10 mL of 0.5%
phosphotungstic acid (PTA) for 30s, air-dried and digital images of
the specimen were observed with a transmission electron
microscope (JEOL model JEM 2010) operated at 200 kV and
equipped with a Gatan MSC 794 CCD camera.
Bacterial Morphology and Membrane Staining Studies
The B. subtilis strain 168 cells were grown in LB medium. The
cultures at an A600 of 0.01 from an overnight culture were
inoculated in the same medium containing different concentra-
tions of the test compounds and grown at 37uC for 4 h. The cells
for morphology studies were harvested and resuspended in 100 mL
of PBS (phosphate buffered saline) buffer containing 0.25%
agarose. For membrane staining, the B. subtilis cells were further
incubated with 1.6 mM of FM 4–64 for an additional 30 min at
37uC without shaking before harvested and resuspended in
100 mL PBS buffer containing 0.25% agarose. 10 mL of the
suspension mixture were then placed on a microscopic slide
pretreated with 0.1% (w/v) poly-L-lysine and the morphology of
the bacterial cells was observed under a phase-contrast optical
microscope at 406 magnification. The images were captured
using an Olympus Bio Imaging Navigator FSX 100 microscope.
Z-ring Visualization in E. coli cells
A culture of E. coli JM109 WM647 containing the IPTG-
inducible plasmid for the overexpression of green fluorescence
protein (GFP)-tagged FtsZ was grown in LB medium supplement-
ed with 30 mg/mL of chloramphenicol. After overnight incuba-
tion, a sample of the culture was diluted to 1% in the LB medium
containing different concentrations of the test compound and
40 mM of IPTG. After 4 h incubation at 37uC, the E. coli cells
were fixed, harvested and resuspended in PBS buffer containing
0.25% of agarose. 10 mL of sample mixture were added to a
pretreated microscopic slide with 0.1% (w/v) poly-L-lysine and
visualized using a fluorescence microscope at 606 oil immersion
magnification with a standard FITC filter set. The images were
captured using an Olympus Bio Imaging Navigator FSX 100
microscope.
Results and Discussion
Rational Design of Berberine Derivatives Using Structure-
based Drug Design
The X-ray crystal structure of S. aureus FtsZ was used in this
study to guide the design of a new series of berberine-based
inhibitors. A previous study suggested that: (1) berberine binds to a
hydrophobic pocket of FtsZ which overlaps with the GTP binding
site; (2) berberine cannot compete with GTP for the binding site,
and (3) the berberine protons on the same flank as the quaternary
ammonium of the isoquinoline core establish fewer contacts with
the FtsZ enzyme than those on the opposite side [30]. As shown in
Figure 1A, the GTP binding site of FtsZ is large enough to
accommodate berberine without competition with the GTP
substrate. However, this cavity is highly solvent exposed and
predominantly polar, with the exception of a region at the top of
the guanine binding site and the N-terminal end of the H7-helix.
The top-scoring poses of berberine docked against the GTP
binding site were found within this hydrophobic region; however,
the protein-ligand shape complementarity was poor and the
docking scores were relatively low. On the other hand, the C-
terminal interdomain cleft is a narrow cavity delimited by a
number of hydrophobic residues from the C-terminal b-sheet, the
T7-loop and the H7-helix (Figure 1A). The shape and physico-
chemical properties of this cavity is particularly suitable for
hydrophobic and planar small-molecules [24]. As shown in
Figure 1B, a good fit was predicted for berberine binding into
the interdomain cleft. Because the shape of the molecule is flat,
Berberine-Based FtsZ Inhibitors
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berberine is particularly suitable to interact with the C-terminal
four-stranded b-sheet of FtsZ. The compound establishes multiple
favorable interactions with the hydrophobic side chains of Ile197,
Leu200, Val203, Leu209, Met226, Leu261, Val297 and Ile311.
The positively charged amine of berberine interacts with Asp199.
Our predicted binding mode is also consistent with the STD NMR
experimental result reported in the previous literature, suggesting
that the berberine protons close to the quaternary ammonium are
less engaged in FtsZ contacts [30]. Indeed, this flank of the
molecule is projected towards the outside of the interdomain cavity
and therefore is less accessible to interact with the protein. Visual
inspection of the docking results reveals that the predicted binding
pose of berberine is surprisingly similar to the experimental
binding pose of PC190723 in S. aureus FtsZ. The molecules share a
similar planarity, shape, length and alignment the ring systems.
Therefore, we hypothesized that berberine binds into the C-
terminal binding cleft, rather than the GTP-binding site, and the
predicted binding mode was thus used for the structure-based
design of new berberine derivatives.
The predicted binding mode of berberine against the inter-
domain cleft of FtsZ suggests that the molecule could be modified
at the C9-position. The C9-methoxy substituent of berberine is
pointing towards the outside of the cavity and binds into a
hydrophobic region delimited by Ile228, Val230 and Val307
(Figure 1C). Because the derivatization of berberine at the C9-
positon is chemically feasible [36,42], we designed a new series of
9-phenoxyalkyl substituted berberine derivatives that are predicted
to bind into the interdomain cleft of FtsZ with good scores
(Figure 1C). Compounds 1–7 were synthesized and their
antimicrobial and anti-FtsZ activities were tested.
Antibacterial Activity of the 9-phenoxyalkyl Substituted
Berberine Derivatives
The antibacterial activity of 9-phenoxyalkyl substituted berber-
ine derivatives 1–7 (Figure 2) was tested against a panel of
clinically relevant bacteria (Table 1). Berberine was tested under
the same assay conditions as a reference compound. Consistent
with the previous literature report, berberine was active against
Gram-positive bacteria but less effective against Gram-negative
bacteria [43]. Berberine derivatives 1–6 bearing the phenoxyalkyl
group at the C9 position were not only more potent against Gram-
negative bacteria, but also exhibited improved efficacy and a
broader spectrum of antibacterial activity than the parent
compound. Compounds 1–6 inhibited the growth of antibiotic-
susceptible and antibiotic-resistant S. aureus strains with MIC
values of 2–8 mg/mL (berberine: 128–196 mg/mL). The growth of
vancomycin-susceptible and vancomycin-resistant E. faecium were
inhibited with MIC values of 4–16 mg/mL (berberine: .196 mg/
mL). Gram-negative strains E. coli and K. pneumoniae (expressing
AmpC b-lactamase) were inhibited with MIC values of 32–
128 mg/mL (berberine: .500 mg/mL). Compound 7 without the
9-phenoxy group was less potent than compounds 1–6, suggesting
that the aromatic ring plays an important role on the antibacterial
activity. Compounds 2 and 5 with chloro- and nitro-substituents
showed slightly stronger antibacterial activity than the other
berberine derivatives. Most importantly, compounds 2 and 5
showed stronger antimicrobial activity than the clinically used
antibiotics ampicillin and vancomycin against antibiotic-resistant
bacteria S. aureus ATCC 29247 and ATCC BAA-41, and E. faecium
ATCC 700221, respectively (Table 1). The same potencies of
compounds 1–6 against antibiotic-sensitive and antibiotic-resistant
S. aureus and E. faecium were found, implying that the berberine
derivatives are not affected by the common mechanisms of
bacterial antibiotic resistance. In summary, the introduction of
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phenoxyalkyl groups at the C9 position of berberine resulted in
substantial improvements in antibacterial activity.
Inhibition of the GTPase Activity of Ftsz
Next, we tested the inhibitory effect of the 9-phenoxyalkyl
substituted berberine derivatives on the GTPase activity of S. aureus
FtsZ. Compounds 1–6 inhibited the GTPase activity with relative
IC50 values between 37.8 and 63.7 mM. Compound 7 lacking the
9-phenoxy substituent was less potent (Table 2). The GTPase
inhibition activity correlates reasonably well with the antimicrobial
activity, suggesting that the compounds interfere with bacterial
growth through a mechanism of FtsZ binding. Berberine was
found to moderately suppress the GTPase activity of S. aureus FtsZ
with a relative IC50 value of 272 mM, which is similar to a previous
literature report [44]. All compounds in this study showed a typical
sigmoidal decrease in the GTPase activity with increasing
concentrations of the compounds. The relative concentration-
response curve obtained with compound 2 against S. aureus FtsZ is
shown in Figure 3. In the absence of compound 2, the GTPase
activity of S. aureus FtsZ was found to be 0.44 GTP/FtsZ/min. As
shown in Figure S3, the GTPase activity of S. aureus FtsZ was
reduced to 0.24 and 0.1 GTP/FtsZ/min in the presence of 25 mM
and 50 mM of compound 2.
GTPase inhibition has also been reported with the antibacterial
cell division inhibitor PC190723 [45]. It has been suggested that
binding into the C-terminal interdomain cleft of FtsZ might
interfere with the protein flexibility, preventing the T7-loop from
exposing important catalytic residues towards the GTP binding
site [26]. Taken together, the results of the GTPase inhibition
assay suggest that the 9-phenoxyalkyl berberine derivatives
establish stronger interactions with the FtsZ enzyme than the
parent berberine, which in turn might lead to a stronger
antimicrobial activity.
Effect of the 9-phenoxyalkyl Berberine Derivatives on the
Polymerization of S. aureus FtsZ
In order to gain further insight into the mechanism of
antibacterial activity of 9-phenoxyalkyl substituted berberine
derivatives, the effects on the self-polymerization activity of the
FtsZ protein were studied. A light scattering assay was used to
detect FtsZ polymerization by monitoring the increase in
absorbance at 600 nm [39]. Berberine has been previously
reported to inhibit the polymerization of E. coli FtsZ [30]. In our
assay conditions berberine was able to moderately block the
polymerization of S. aureus FtsZ, with approximately 30%
inhibition at 200 mM concentration. On the other hand,
Table 2. Effects of compounds 1–7 on S. aureus FtsZ GTPase
activity.
Compound IC50±SEM
a (mM)
1 56.8610.4
2 37.863.8
3 47.364.6
4 63.764.8
5 43.465.2
6 63.564.7
7 240.4363.3
Berberine 272646.6
Berberine was tested as a reference molecule.
aSEM: standard error of the mean.
doi:10.1371/journal.pone.0097514.t002
Figure 3. Concentration-response curve of compound 2 against the GTPase activity of S. aureus FtsZ. Each point represents the mean of
three independent assays, and the vertical bars show the standard derivation of the mean.
doi:10.1371/journal.pone.0097514.g003
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compounds 1–5 at 50 mM extensively inhibited the polymerization
of S. aureus FtsZ. The inhibition was maximal with compound 2
(,70% inhibition, Figure 4A). The non-FtsZ-targeting antibiotic
ampicillin was used in the same assay condition as a negative
control. As expected, 1 mM of ampicillin had no effect on the
polymerization of S. aureus FtsZ. Moreover, the inhibition of S. aureus
FtsZ polymerization by compound 2 was further investigated at
increasing concentrations of the molecule. As shown in Figure 4B,
compound 2 strongly inhibited the S. aureus FtsZ polymerization in a
dose-dependent manner. In order to confirm that the underlying
mechanism for inhibition of FtsZ polymerization by berberine or
compound 2 is not related with the formation of aggregates, similar
light scattering experiments were conducted in the presence of
0.01% Triton X-100, a natural detergent that has been shown to
disrupt aggregate formation in enzymatic assays [40]. As shown in
Figure S1, the inhibition of polymerization by berberine and
compound 2 was maintained in the presence of Triton X-100, at
different concentrations of the compounds in a dose-dependent
manner. These results suggest that the mechanism of inhibitory
activity of berberine and its derivative 2 on FtsZ is specific rather
than caused by aggregation of the compounds.
The effects of 9-phenoxyalkyl substituted berberine derivatives
on the polymerization of FtsZ were also analyzed by transmission
electron microscopy. In the absence of the test compounds, a
dense network of FtsZ protofilaments with an average width of
120624 nm was observed (Figure 5A). Compounds 1 and 2 were
found to drastically reduce the size and thickness of the FtsZ
polymers and the bundling of FtsZ protofilaments at much lower
concentrations than their parent compound berberine. Com-
pounds 1 (8.8 mM) and 2 (4 mM) reduced the thickness of the
bundles of FtsZ protofilaments by 60% to 70% respectively
(Figures 5C and 5D). Only a few thin and short FtsZ filaments
were observed in the presence of 2.
Effects on the Morphology and Membrane Structure of B.
subtilis Cells
The underlying mechanism of the antibacterial activity of
compound 2 was further explored by microscopic observation of
the bacterial cell morphology. Compound 2 significantly increased
the cell length of B. subtilis (Figure. 6B), as compared to the
untreated cells (Figure 6A), suggesting a mechanism of antibac-
terial-induced cell filamentation. It is interesting to note that
similar results were also found with FtsZ inhibitors from different
chemotypes, such as OBTA and PC190723 [17,46]. This result
strongly suggests that 9-phenoxyalkyl substituted berberine deriv-
atives interact in vivo with the bacterial FtsZ protein. Because
perturbation of membrane structure can also lead to bacterial cell
lysis and death, the effect of compound 2 on the bacterial cell
membrane was further investigated using a red fluorescent dye
FM4264. In spite of an increased length of B. subtilis cells
(Figure 6D), compound 2 did not induce any detectable
perturbation of the cell membrane, as compared to untreated
Figure 4. Effect of 9-phenoxyalkyl berberine derivatives on the polymerization of S. aureus FtsZ. (A) Effect on the polymerization of S.
aureus FtsZ in the absence of (vehicle - 1% DMSO) or in the presence of 50 mM of compounds 1–5, 200 mM of berberine or 1 mM of ampicillin are
shown. (B) The polymerizations of S. aureus FtsZ in the presence of compound 2 at 10 mM, 25 mM, and 50 mM are shown.
doi:10.1371/journal.pone.0097514.g004
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cells (Figure 6C). These results confirm that compound 2 inhibits
bacterial proliferation by inducing cell filamentation in B. subtilis
without perturbing the bacterial membrane.
Effects on E. coli Z-ring Formation
To confirm that 9-phenoxyalkyl substituted berberine deriva-
tives target at the FtsZ protein in vivo, the formation of the
dynamic Z-ring in the Gram-negative E. coli cells was studied.
During bacterial cell division, rod-shaped E. coli initializes a
septum formation by the dynamic Z-ring. Previous studies have
shown that perturbation of the FtsZ function could lead to the
inhibition of bacterial proliferation by a mechanism of interference
with the Z-ring formation [14,30,46]. In the absence of compound
2, a green fluorescent band of GFP-tagged FtsZ was visible at the
cell midpoint (Figure 7A). The fluorescent bands represent
septation-competent localized Z-rings (cytoskeletal structures). In
the presence of 48 mM of compound 2, GFP-tagged FtsZ
dispersed as discrete foci throughout the elongated cells
(Figures 7B and Figure S2), indicating that compound 2 caused
mislocalization of the FtsZ protein.
Taken together, the in vivo and in vitro results confirmed the role of
9-phenoxyalkyl substituted berberine derivatives as FtsZ inhibitors,
with much stronger potency than the parent compound berberine.
Conclusion
Natural products and semi-synthetic derivatives provide a rich
source of bioactive compounds for the development of new
antibacterial agents. However, in the past decade most of the new
chemical entities that reached the clinical practice were derived
from the same natural scaffolds [47]. Berberine has been
traditionally used to treat microbial infections. At the doses
commonly used, the compound is considered safe [27,48]. Recent
studies confirmed that berberine is a moderate inhibitor of FtsZ, an
important bacterial cell division protein. In this study, molecular
docking simulations suggested that berberine binds into the C-
terminal interdomain cleft of FtsZ, projecting the 9-methoxy group
towards the outside of the cavity. Based on the docking results, a
new series of 9-phenoxyalkyl berberine derivatives was hypothesized
to establish additional favorable interactions with FtsZ.
The 9-phenoxyalkyl substituted derivatives exhibited potent
antimicrobial activity against Gram-positive bacterial strains such
as ampicillin- and methicillin-resistant S. aureus, and broader
spectrum of activity than the parent compound berberine.
Biochemical evaluations demonstrated that the new berberine
derivatives target the bacterial FtsZ protein. The compounds were
potent inhibitors of the GTPase activity of FtsZ and were able to
inhibit the FtsZ polymerization in a dose-dependent manner.
These results suggest that the binding of berberine derivatives into
the interdomain cleft interferes with the GTPase activity of FtsZ,
which in turn destabilizes the formation of FtsZ polymers. In
summary, the results of this study demonstrate the potential of the
berberine scaffold for chemical optimization into potent inhibitors
of FtsZ with broad-spectrum antibacterial activity.
Supporting Information
Figure S1 Control experiments in the absence and in the
presence of 0.01% Triton X-100 to study the effect of berberine
Figure 5. Electron micrographs of S. aureus FtsZ polymers in the
absence and in the presence of berberine and compound 1–2.
(A) vehicle (1% DMSO). (B) 200 mM of berberine. (C) 8.8 mM of
compound 1. (D) 4 mM of compound 2. The length of the scale bar is
1000 nm.
doi:10.1371/journal.pone.0097514.g005
Figure 6. Effects of compound 2 on the cell morphology and
membrane structure of B. subtilis. B. subtilis strain 168 cells were
grown in the absence (A) or in the presence of 4 mM of compound 2 (B).
Observations after membrane staining with the red fluorescent dye FM
4264 are shown in the absence (C) or in the presence of 4 mM of
compound 2 (D). The length of the scale bar is 10 mm.
doi:10.1371/journal.pone.0097514.g006
Figure 7. Effects of compound 2 on the Z-ring formation of E.
coli. Perturbation of cytokinetic Z-ring formation in E. coli cells was
visualized using green fluorescent GFP-tagged FtsZ. The bacterial cells
were grown in the absence (A) or in the presence of 48 mM of
compound 2 (B). The length of the scale bar is 10 mm.
doi:10.1371/journal.pone.0097514.g007
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and its 9-phenoxyalkyl derivative 2 on the polymerization of S.
aureus FtsZ. (A) Effect on the polymerization of S. aureus FtsZ by
200 mM and 500 mM of berberine. (B) Effect on the polymeriza-
tion of S. aureus FtsZ by 10 mM and 25 mM of compound 2.
(TIF)
Figure S2 Effects of compound 2 on the Z-ring formation of E.
coli. Perturbation of cytokinetic Z-ring formation in E. coli cells was
visualized using green fluorescent GFP-tagged FtsZ. The bacterial
cells were grown in the presence of 48 mM of compound 2. The
length of the scale bar is 10 mm.
(TIF)
Figure S3 Inhibition of S. aureus FtsZ GTPase activity by 25 mM
and 50 mM of compound 2 at increasing FtsZ concentrations.
(TIF)
Text S1 Supplemental information, including synthesis of
berberine derivatives, 1H NMR and mass spectra of berberine
derivatives and references.
(PDF)
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